# Elite Technology-Transfer Dossier v2 — P-25

**Schema:** ELITE_TECHNOLOGY_TRANSFER_DOSSIER_v2
**R346 upgrades:** {"ownership_made_factual": true, "economic_hypothesis_added": true, "regulatory_firewall_installed": true, "buyer_actions_corrected": true, "independent_qa_performed": true}
**Three axes:** T1-FAIL / CO_DEVELOPMENT_REQUIRED / UNCONTACTED

---

## R346 Integrity Upgrades

### Ownership (Gate 1 — factual, not assumed)
- **Ownership status:** UNVERIFIED
- **Reason:** No IP assignment records verified. No patent filings confirmed. CEO must verify ownership before any license/acquisition discussion.
- **Patent status:** NO_PATENT_FILED — we are not running a patent court
- **FTO status:** UNVERIFIED — buyer counsel must perform freedom-to-operate analysis
- **Counsel review:** Full IP diligence by buyer counsel REQUIRED before any commercial engagement

### Economic Hypothesis (Gate 2)
- **Buyer:** Sensor OEM (Codman, Medtronic, Raumedic)
- **Use case:** Self-referencing pressure sensor with drift cancellation
- **Economic driver:** Reduction in sensor drift extending implantable monitoring lifetime
- **Current solution cost:** $50K per sensor replacement (SOURCE_DERIVED)
- **Potential value driver:** 67.8% drift cancellation (MODELLED — FAILS 2.0 mmHg threshold at 3.45 mmHg)
- **Source:** R337/g4_p25_model
- **Confidence:** MODELLED — T1-FAIL, mechanism limitation identified (biofouling)
- **Unknowns:** ['Whether anti-fouling coating brings error below 2.0 mmHg', 'Whether mechanism survives for trending-only application']

### Regulatory Firewall (Gate 3)
- **Facts:** []
- **Hypotheses:** 2 preliminary hypotheses (counsel must confirm)
- **Unknowns:** 6 items
- **Counsel required:** Buyer regulatory counsel REQUIRED to confirm classification, predicate, and testing strategy. Preliminary assessment only — not a regulatory opinion.

### Buyer Action (Gate 6 — fixed)
- **Action:** Commission the repair experiment ($8,000 (ESTIMATED)) OR request co-development discussion to address the known mechanism limitation. Licensing is not appropriate until the mechanism limitation is res
- **Recommended path:** COMMISSION_REPAIR_EXPERIMENT → CO_DEVELOP → LICENSE IF REPAIR SUCCEEDS

### Independent QA (Gate 4)
- **QA passed:** True
- **Claim-evidence links checked:** 2
- **Errors:** NONE
- **Warnings:** NONE
- **Unsupported claims:** NONE
- **Semantic promotions:** NONE
- **Ownership issues:** NONE
- **Regulatory issues:** NONE
- **Economic issues:** NONE
- **Contradictions:** NONE

---

## Buyer Decision Card (v2)

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
BUYER DECISION CARD (v2 — R346 integrity pass)
P-25
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

**TECHNOLOGY**
P-25 — Self-referencing piezoresistive pressure sensor. Dual-element differential measu

**WHY YOU MAY CARE**
A P-25 mechanism whose current model fails the target but may survive with additional repair work.

**CURRENT EVIDENCE**
  Technical readiness: T1-FAIL
  Physical validation: NONE
  Transfer posture: CO_DEVELOPMENT_REQUIRED

**WHAT IS NOT PROVEN**
  - Falsification threshold (2.0 mmHg) NOT met — 3.45 mmHg error
  - Biofouling dominates non-common-mode drift
  - Self-referencing alone insufficient for absolute pressure measurement

**STRONGEST ALTERNATIVE**
  Periodic recalibration protocol (existing clinical practice) — inconvenient but reliable

**DECISIVE QUESTION**
  Whether anti-fouling coating or periodic recalibration can bring error below 2.0 mmHg. If not, mechanism is falsified for absolute measurement (may survive for trending only).

**ECONOMIC HYPOTHESIS**
  Driver: Reduction in sensor drift extending implantable monitoring lifetime
  Current cost: $50K per sensor replacement (SOURCE_DERIVED)
  Potential value: 67.8% drift cancellation (MODELLED — FAILS 2.0 mmHg threshold at 3.45 mmHg)
  Confidence: MODELLED — T1-FAIL, mechanism limitation identified (biofouling)

**REGULATORY STATUS** (preliminary — counsel must confirm)
  HYPOTHESIS: Device classified as Class II — Counsel must confirm.
  HYPOTHESIS: 510(k) pathway likely — 'Likely' is a hypothesis. Buyer regulatory counsel must confirm predicate selection and substantial equivalence strategy.

**OWNERSHIP STATUS**
  UNVERIFIED — No IP assignment records verified. No patent filings confirmed. CEO must verify ownership before any license/acquisition discussion.
  Patent status: NO_PATENT_FILED — we are not running a patent court
  FTO status: UNVERIFIED — buyer counsel must perform freedom-to-operate analysis

**COST TO ANSWER**
  $8,000 (ESTIMATED)

**TIME**
  12 weeks (ESTIMATED — 30-day soak + analysis)

**IF PASS**
  Advance to next development phase (see Development Plan)

**IF FAIL**
  Repair / redesign / terminate (see Failure Record)

**WHAT WE ARE ASKING YOU TO DO**
  Commission the repair experiment ($8,000 (ESTIMATED)) OR request co-development discussion to address the known mechanism limitation. Licensing is not appropriate until the mechanism limitation is resolved.

**BUYER_ACTION_ID**
  BA-P25-001

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

---

*This is v2 of the elite dossier. R346 applied: factual ownership, economic hypothesis, regulatory firewall, fixed buyer actions, independent QA. See R345 full dossier for Sections 01–15 baseline content.*
